계명대학교 의학도서관 Repository

국내 전이성 투명세포 신장암 환자의 1차 표적치료제 동향: Sunitinib과 Pazopanib, 다기관 연구

Metadata Downloads
Author(s)
Minsu ChoiTeak Jun ShinByung Hoon KimChun Il KimKyung Seop LeeSeock Hwan ChoiHyun Tae KimTae-Hwan KimTae Gyun KwonYoung Hwii KoYoon Soo HahJae-Shin ParkSe Yun Kwon
Keimyung Author(s)
Shin, Teak JunKim, Byung HoonKim, Chun Il
Department
Dept. of Urology (비뇨의학)
Journal Title
Korean J Urol Oncol
Issued Date
2022
Volume
20
Issue
2
Keyword
Metastatic clear cell RCCSunitinibPazopanib
Abstract
Purpose:
There have been few reports on comparison between sunitinib and pazopanib as first-line targeted therapy in Korean metastatic clear cell renal cell carcinoma (ccRCC). We sought to analyze the treatment trends of metastatic ccRCC by comparing the effects and adverse events of sunitinib and pazopanib.

Materials and Methods:
Data of 357 metastatic RCC patients who received the sunitinib or pazopanib as the first-line targeted therapy from the Daegyeong Oncology Study Group database was obtained and analyzed. Among these patients, patients who only clear cell type was confirmed after needle biopsy or nephrectomy were included, and patients who underwent target therapy for less than 3 months were excluded.

Results:
Of 251 patients who met the inclusion criteria, sunitinib and pazopanib group were identified in 156 (62%) and 95 patients (38%), respectively. Pazopanib group was older (66 years vs. 61 years, p=0.001) and more symptomatic (65% vs. 52%, p=0.037) and had more patients with Karnofsky performance status <80 (20% vs. 11%, p=0.048) and fewer number of organ metastases (p=0.004) compared to sunitinib group. There was no significant difference in disease control rate (88.5% vs. 87.3%, p=0.744), the median progression-free survival (19 months vs. 15 months, p=0.444) and overall survival (25 months vs. 19 months, p=0.721) between sunitinib and pazopanib. The most common grade 3/4 adverse events with sunitinib and pazopanib were anemia (5%) and hand-foot syndrome (3%), respectively. There was no significant difference between sunitinib and pazopanib in number of patients who experienced grade 3/4 adverse events (15% vs. 11%, p=0.275). However, there were more patients who discontinued treatment due to only adverse events in sunitinib group compared to pazopanib group (12% vs. 3%, p=0.020).

Conclusions:
In Korean metastatic ccRCC, pazopanib tended to be used in patients with poorer health status compared to sunitinib. Sunitinib and pazopanib had no significant difference in treatment effect and survival, but pazopanib had more tolerable adverse events.
Alternative Title
Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study
Keimyung Author(s)(Kor)
신택준
김병훈
김천일
Publisher
School of Medicine (의과대학)
Citation
Minsu Choi et al. (2022). 국내 전이성 투명세포 신장암 환자의 1차 표적치료제 동향: Sunitinib과 Pazopanib, 다기관 연구. Korean J Urol Oncol, 20(2), 115–122. doi: 10.22465/kjuo.2022.20.2.115
Type
Article
ISSN
2234-4977
Source
https://www.kjuo.or.kr/journal/view.php?doi=10.22465/kjuo.2022.20.2.115
DOI
10.22465/kjuo.2022.20.2.115
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/44255
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.